Business
Unicycive Therapeutics to Present Three Posters at the American Society of Nephrology (ASN) Kidney Week 2024
LOS ALTOS, Calif., Aug. 26, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies
About this update from Unicycive Therapeutics, Inc.
[{"type":"text","content":"LOS ALTOS, Calif., Aug. 26, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company” or “Unicycive”), today announced that three poster presentations will be delivered on the Company’s product candidates at the American Society of Nephrology (ASN) Kidney Week 2024 taking place October 24-27, 2024 in San Diego, CA. “Data from both oxylanthanum carbonate (OLC) and UNI-494 continue to garner strong interest from the medical community, and we look forward to presenting our data at Kidney Week, one of the most prominent meetings in our field,” said Shalabh Gupta, MD, Chief Executive Officer of Unicycive. Title:Intravenous UNI-494 Slows the Progression or Halts/Reverses Acute Kidney Injury When Administered After Ischemia/Reperfusion in RatsLead Author:Satya Medicherla, Ph.D., Vice President, Preclinical Pharmacology, UnicyciveSession Title:AKI: MechanismsPoster Board:#FR-PO155Date/Time:Friday, October 25, 2024 from 10:00 a.m. – 12:00 p.m. PT Title:Combination Oxylanthanum Carbonate and Tenapanor Lowers Urinary Phosphate Excretion in RatLead Author:Satya Medicherla, Ph.D., Vice President, Preclinical Pharmacology, UnicyciveSession Title:CKD-MBD: Basic and TranslationalPoster Board:#SA-PO243Date/Time:Saturday, October 26, 2024 from 10:00 a.m. – 12:00 p.m. PT Title:UNI-494 Phase I Safety, Tolerability, and PharmacokineticsLead Author:Guru Reddy, PH.D., Vice President of Preclinical R&D, UnicyciveSession Title:AKI: Clinical, Outcomes, and Trials - ManagementPoster Board:#SA-PO036Date/Time:Saturday, October 26, 2024 from 10:00 a.m. – 12:00 p.m. PT About Oxylanthanum Carbonate (OLC) Oxylanthanum carbonate is a next-generation lanthanum-based phosphate binding agent utilizing proprietary nanoparticle technology being developed for the treatment of hyperphosphatemia in patients with chronic kidney disease (CKD). OLC has over forty issued and granted patents globally. Its potential best-in-class profile may have meaningful patient adherence benefits over currently available treatment options as it requires a lower pill burden for patients in terms of number and size of pills per dose that are swallowed instead of chewed. Based on a survey conducted in 2022, Nephrologists stated that the greatest unmet need in the treatment ...